Compare UK prices. 40+ products · 22 retailers scored
PeptideClear UK

Encyclopedia entry

Epitalon

Evidence: Animal only
AI-friendly summary · Epitalon

Epitalon (also spelled Epithalon) is a tetrapeptide synthesised in 1980 by Vladimir Khavinson at the St Petersburg Institute of Bioregulation and Gerontology. Roughly 60 PubMed papers cover the molecule, focused on pineal-gland function, melatonin regulation and telomerase activity, almost all from a single research school. No phase II or phase III randomised human clinical trials have been published in mainstream Western journals.

Mechanism of action

How Epitalon works

Epitalon is proposed to regulate pineal gland function and downstream melatonin output, with a separate hypothesised effect on telomerase activity in human somatic cell cultures (Khavinson 2003). The mechanistic claims rest on a body of in vitro and animal-model work from the originating Russian research school; the human translational evidence is methodologically thin and independent Western replication is absent for most of the headline findings.

Source: Khavinson VK et al. (telomerase activation in human cell cultures, 2003)

What the literature claims

Roughly 60 PubMed papers cover Epitalon since the molecule was synthesised in 1980. The Khavinson group has produced lifespan-extension data in rodent and avian models alongside in vitro telomerase activation work, and circadian regulation findings in animal models. Cancer-incidence reduction claims appear in long-running rodent studies. Treat all of this as preliminary findings from a single research school rather than established science.

The literature is methodologically thin compared to mainstream peptide research. Independent replication is the persistent gap. Treat the published claims as preliminary findings from a single research school rather than established science.

UK regulatory status

  • · Not controlled under UK law.
  • · No UK marketing authorisation.
  • · Sold by UK research-peptide retailers under "research use only" framing.
  • · Not on the WADA prohibited list as of the 2026 list.

Risks and unknowns

What the literature does not yet show about Epitalon

Known concerns

Open questions in the literature

Regulatory note

Not controlled under UK law. No UK marketing authorisation. Sold legally as a research chemical when marketed without therapeutic claims. Becomes an unlicensed medicinal product the moment a retailer or commentator makes therapeutic claims about it.

Important: PeptideClear publishes encyclopedia commentary only and does not recommend human use. Speak to a UK-registered prescriber before any medical decision.

Where to learn more

Frequently asked questions

Is Epitalon legal in the UK?
Epitalon is not controlled under the Misuse of Drugs Act 1971 and is not scheduled under the Psychoactive Substances Act 2016. It is sold by UK research peptide retailers under "research use only, not for human or animal consumption" framing. It holds no UK marketing authorisation.
What does the human evidence show for Epitalon?
No phase II or phase III randomised human clinical trials on Epitalon have been published in mainstream Western peer-reviewed journals. The Khavinson group has published observational and case-series work in Russian-language journals, but the rigorous evidence base most prescribers and regulators would require is absent. The literature is methodologically thin compared to mainstream peptide research.
What is the regulatory status of Epitalon?
Epitalon has no UK marketing authorisation as a medicine. It is sold as a research chemical when marketed without therapeutic claims. It is not on the WADA prohibited list as of the 2026 list. The moment a UK retailer attaches a longevity or anti-ageing claim it becomes an unlicensed medicinal product.
What forms is Epitalon available in?
UK research peptide retailers list Epitalon most commonly as lyophilised powder in 10mg or 50mg vials for reconstitution. Some retailers also list oral capsule and sublingual formulations. PeptideClear publishes no dosing or human-use instructions; this is encyclopedia commentary only.
Where can I learn more about Epitalon?
Vladimir Khavinson at the St Petersburg Institute of Bioregulation and Gerontology has authored most of the published literature since synthesising the tetrapeptide in 1980. A PubMed search for "epitalon" or "epithalon" returns roughly 60 papers, the majority from the Khavinson group. Critical reviews from mainstream Western literature are sparse.

Clinical evidence record

Read the clinical evidence record for Epitalon

Top peer-reviewed citations, mechanism of action, structured UK regulatory status. Machine-readable companion to this encyclopedia entry.

Popular on PeptideClear

Reviewed by Oliver Mackman, editorial director · last reviewed 2026-05-26T12:00:00.000Z
Trust, Legal and Governance

PeptideClear is a trading name of Best Business Loans Ltd, registered in England and Wales (company number 16833937). All services, operations and publications under the PeptideClear brand are delivered by Best Business Loans Ltd.

Legal and Registration

Registered in England and Wales. Company number 16833937. D‑U‑N‑S 234324824. ICO registered, reference ZC151816 (certificate, verify). Registered supplier on the UK Government's Find a Tender Service (FTS). Details publicly available via Companies House and OpenCorporates.

Standards and Governance

Operates under UK data protection and consumer standards. Aligns with UK GDPR, ISO 27001 and ISO 9001 principles. Working towards Cyber Essentials certification.

Domain Continuity

Primary domain peptideclear.co.uk. Business ownership, entity and services remain unchanged. Reviewed quarterly.